Sloan, A., Buerki, R., Landi, D., Desjardins, A., Friedman, A., Ambady, P., … Nichols, W. G. (2021). LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. In NEURO-ONCOLOGY (Vol. 23, pp. 53–54).

Sloan, Andrew, Robin Buerki, Daniel Landi, Annick Desjardins, Allan Friedman, Prakash Ambady, Kevin Becker, et al. “LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA.” In NEURO-ONCOLOGY, 23:53–54, 2021.

Sloan A, Buerki R, Landi D, Desjardins A, Friedman A, Ambady P, et al. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. In: NEURO-ONCOLOGY. 2021. p. 53–4.

Sloan, Andrew, et al. “LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA.” NEURO-ONCOLOGY, vol. 23, 2021, pp. 53–54.

Sloan A, Buerki R, Landi D, Desjardins A, Friedman A, Ambady P, Becker K, Butowski N, Cavaliere R, Curry W, Ong S, Vega R, Wen P, Bockorny B, Chiocca EA, Elder JB, Bulsara K, Berger M, Gerstner E, Sauvageau E, Kelly A, Mixson L, Jackson L, Learn C, Dickinson A, Nichols WG. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. NEURO-ONCOLOGY. 2021. p. 53–54.